On October 4, Italian Recordati reached an agreement with Sanofi to acquire the global rights to the autoimmune disease drug Enjaymo (sutimlimab).According to the terms of the agreement, if net sales reach or exceed the upper limit of the peak year sales forecast, Recordati will pay an upfront payment of $825 million and additional commercial milestone payments of up to $250 million. The transaction is expected to be completed by the end of 2024, subject to regulatory approval.Recordati CEO Rob Koremans said:"This transaction aligns with our broader strategy, reaffirms our commitment to the rare disease space, and complements our oncology portfolio, particularly Sylvant®. Enjaymo further expands our rare disease footprint in the U.S., Japan, and Europe, and will make a positive contribution to our revenue and profits. Most importantly, Enjaymo has strong clinical attributes as the only approved product for the treatment of CAD, addressing a significant unmet medical need for patients suffering from this debilitating disease."
Enjaymo® is a humanized monoclonal antibody designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. Enjaymo isThe only targeted product approved for the treatment of Cold Agglutinin Disease (CAD), a rare B-cell lymphoproliferative disorder that causes the body's immune system to attack its own red blood cells.In 2022,EnjaymoApproved by the U.S. FDA, the European EMA, and Japan's Ministry of Health, Labour and Welfare.As of 2023In the 12 months of August, Enjaymo's revenue was approximately 100 million euros (110.3 million US dollars), and it is expected to generate more than 150 million euros in revenue in the fiscal year 2025.Its peak sales potential is between 250 million and 300 million euros.Recordati expects a small revenue contribution this year and says the deal will immediately add to earnings before interest, taxes, depreciation, and amortization.Follow the official account below to see the world!
